Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus
Abstract Hepatitis E virus (HEV) infection is a major cause of acute viral hepatitis worldwide. The efficacy and safety of the HEV239 vaccine have been validated, with protection lasting at least 10 years. This study extended the phase 3 trial of HEV239 (NCT01014845), presenting data on the durabili...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-024-01041-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|